InsiderTrades

Form 4 for AVIR Atea Pharmaceuticals, Inc.

Accepted 2024-02-02 00:00:00 ET · period of report 2024-01-31 · accession 0000950170-24-010973 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-02 2024-02-01 AVIR Corcoran Andrea See Remarks S - Sale+OE $3.84 -15.8K 670.2K -2% -$60.8K
D 2024-02-02 2024-01-31 AVIR Corcoran Andrea See Remarks M - OptEx — +44.4K 686.1K +7% —
D 2024-02-02 2024-01-31 AVIR Corcoran Andrea See Remarks M - OptEx $0.00 -44.4K 88.7K -33% $0
D 2024-02-02 2024-01-31 AVIR Corcoran Andrea See Remarks A - Grant $0.00 +200.0K 200.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-01 S D 15,843 $3.84 670,208 D — — (F3) Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.
2 Common Common Stock 2024-01-31 M A 44,367 — 686,051 D — — (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F2) Includes 8,680 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
3 Derivative Restricted Stock Units 2024-01-31 M D 44,367 $0.00 88,733 D — · — to — 44,367 Common Stock (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F4) The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
4 Derivative Stock Option (Right to Buy) 2024-01-31 A A 200,000 $0.00 200,000 D $4.16 · — to 2034-01-30 200,000 Common Stock (F5) The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.